thalidomide has been researched along with Cardiotoxicity in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigated the influence of apremilast against doxorubicin-induced cardiotoxicity in male Wistar rats." | 7.88 | Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways. ( Al-Anazi, WA; Al-Asmari, AF; Al-Harbi, MM; Al-Harbi, NO; Almutairi, MM; Alotaibi, MR; Alsaad, AM; Alshammari, M; Ansari, MA; Ansari, MN; Bahashwan, S; Imam, F; Khan, MR, 2018) |
| " The aim of the present study was to investigate the possible protective effect of apremilast (AP) on the CFZ -induced cardiotoxicity." | 7.83 | Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F, 2016) |
| "The present study investigated the influence of apremilast against doxorubicin-induced cardiotoxicity in male Wistar rats." | 3.88 | Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways. ( Al-Anazi, WA; Al-Asmari, AF; Al-Harbi, MM; Al-Harbi, NO; Almutairi, MM; Alotaibi, MR; Alsaad, AM; Alshammari, M; Ansari, MA; Ansari, MN; Bahashwan, S; Imam, F; Khan, MR, 2018) |
| " The aim of the present study was to investigate the possible protective effect of apremilast (AP) on the CFZ -induced cardiotoxicity." | 3.83 | Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imam, F | 2 |
| Al-Harbi, NO | 2 |
| Al-Harbi, MM | 2 |
| Ansari, MA | 2 |
| Al-Asmari, AF | 1 |
| Ansari, MN | 2 |
| Al-Anazi, WA | 1 |
| Bahashwan, S | 1 |
| Almutairi, MM | 2 |
| Alshammari, M | 2 |
| Khan, MR | 1 |
| Alsaad, AM | 1 |
| Alotaibi, MR | 1 |
| Almukhlafi, TS | 1 |
| Aljerian, K | 1 |
| Ahmad, SF | 1 |
| Reneau, JC | 1 |
| Asante, D | 1 |
| van Houten, H | 1 |
| Sangaralingham, LR | 1 |
| Buadi, FK | 1 |
| Lerman, A | 1 |
| Herrmann, J | 1 |
3 other studies available for thalidomide and Cardiotoxicity
| Article | Year |
|---|---|
Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways.
Topics: Animals; Apoptosis; Cardiotoxicity; Caspase 3; Catalase; Dose-Response Relationship, Drug; Doxorubic | 2018 |
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicit | 2016 |
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; H | 2017 |